Safety and Efficacy of ombitasvir/paritaprevir/ritonavir with or without dasabuvir Plus ribavirin in hepatitis C virus genotype 1 or 4 infected patients with compensated cirrhosis : ABACUS compassionate-use nationwide Italian programme

Status: Completed

Phase of Trial: Clinical Phase Unknown

Latest Information Update: 01 Jun 2018

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dasabuvir (Primary) ; Ombitasvir/paritaprevir/ritonavir (Primary) ; Ribavirin (Primary)
Indications Hepatitis C
Focus Expanded access; Therapeutic Use

Most Recent Events

28 May 2018 Results (n=240) assessing safety and efficacy of treatment based on ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in the sub-group of GT1 patients older than 65 years, were published in the Infection
03 Feb 2017 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight